Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

What impact will new US tariffs have on global markets? How did Apple manage $1 billion tariff costs last quarter? Why are Amazon shares falling despite beating earnings? What caused Figma’s IPO to triple in value? How will Trump’s 35% tariffs on Canada affect trade? Why is Microsoft hitting a $4 trillion valuation now? How is AI spending boosting Meta and Microsoft revenues?

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

benzinga.com/m-a/25/07/46701164/bausch-health-adds-late-stage-ready-alcohol-liver-disease-drug-candidate-in-63-million-durect-buyout

Bausch Health Companies Inc. (NYSE:BHC) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:DRRX), including a novel therapeutic molecule, larsucosterol.
Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic…

This story appeared on benzinga.com, 2025-07-29 18:21:25.